The lipidomic changes during Ramadan diurnal intermittent fasting (RIF) among obese individuals.
BioNTech exits PD-L1 development with Genmab as Q2 revenues drop – Pharmaceutical Technology
In a Q2 financial report, BioNTech announced that it would quit the joint development of acasunlimab with Genmab as it focuses on its antibody drug